ELVN

Enliven Therapeutics, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Collins Helen LouiseCHIEF MEDICAL OFFICER
$137k3.5k shares
SellMay 18, 2026
$39.53
--
Collins Helen LouiseCHIEF MEDICAL OFFICER
$52k1.3k shares
SellMay 18, 2026
$40.25
--
Collins Helen LouiseCHIEF MEDICAL OFFICER
$9.2k223 shares
SellMay 18, 2026
$41.21
--
Collins Helen LouiseCHIEF MEDICAL OFFICER
$117k2.4k shares
SellApr 17, 2026
$48.06
--
Collins Helen LouiseCHIEF MEDICAL OFFICER
$115k2.4k shares
SellApr 17, 2026
$47.39
--
Collins Helen LouiseCHIEF MEDICAL OFFICER
$6.4k140 shares
SellApr 17, 2026
$45.81
--

News

prnewswire.comEnliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Sharesprnewswire.comJun 15gurufocus.comEnliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrantsgurufocus.comJun 11prnewswire.comEnliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrantsprnewswire.comJun 11prnewswire.comEnliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrantsprnewswire.comJun 11seekingalpha.comEnliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcriptseekingalpha.comJun 11